Cinclus Pharma Holding AB (FRA:J8P) Total Liabilities: €21.41 Mil (As of Mar. 2026)


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
4 GF Score
Price €1.00
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Total Liabilities?

Cinclus Pharma Holding AB FRA:J8P +1.62% 4 Total Liabilities is €21.41 Mil as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 4/100. The stock has 3 warning signs investors should review.

Cinclus Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2026 was €21.41 Mil.

Cinclus Pharma Holding AB's quarterly Total Liabilities increased from Sep. 2025 (€14.36 Mil) to Dec. 2025 (€16.28 Mil) and increased from Dec. 2025 (€16.28 Mil) to Mar. 2026 (€21.41 Mil).

Cinclus Pharma Holding AB's annual Total Liabilities declined from Dec. 2023 (€15.31 Mil) to Dec. 2024 (€3.97 Mil) but then increased from Dec. 2024 (€3.97 Mil) to Dec. 2025 (€16.28 Mil).

Cinclus Pharma Holding AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Total Liabilities Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
1.96 5.36 15.31 3.97 16.28

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 13.69 14.36 16.28 21.41
FRA:J8P
4GF Score
Cinclus Pharma Holding AB FRA:J8P
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cinclus Pharma Holding AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.57+(0.44+3.27
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=16.28

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=50.224-33.944
=16.28

Cinclus Pharma Holding AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.15+(0.368+4.889
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=21.41

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=47.5-26.093
=21.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €21.41 Mil mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Total Liabilities of €21.41 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Total Liabilities too high?
Cinclus Pharma Holding AB's current Total Liabilities is €21.41 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Total Liabilities compare to ZTS and UTHR?
Cinclus Pharma Holding AB's Total Liabilities of €21.41 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Total Liabilities is €21.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Total Liabilities of €21.41 Mil. The current Total Liabilities is €21.41 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 4/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Total Liabilities is €21.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
4GF Score

Get the complete analysis for FRA:J8P

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.00
Price